{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:34:39Z","timestamp":1791387279768,"version":"4.3.3"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jcv.2019.09.008","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T11:38:03Z","timestamp":1568979483000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay"],"prefix":"10.1016","volume":"120","author":[{"given":"I.","family":"Benoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-679X","authenticated-orcid":false,"given":"L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vanden Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-7564","authenticated-orcid":false,"given":"M.","family":"Poljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"O\u0161trbenk Valen\u010dak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arbyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2019.09.008_bib0005","first-page":"1","article-title":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents: a review of human carcinogens","volume":"100B","year":"2012","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum."},{"issue":"Suppl 5","key":"10.1016\/j.jcv.2019.09.008_bib0010","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding HPV testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2019.09.008_bib0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol."},{"issue":"November","key":"10.1016\/j.jcv.2019.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ajog.2004.05.018","article-title":"Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer","volume":"191","author":"Castle","year":"2004","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"February (4)","key":"10.1016\/j.jcv.2019.09.008_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/jnci\/djn486","article-title":"Prognostic value of measuring load of human papillomavirus DNA in cervical samples: an elusive target","volume":"101","author":"Franco","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"Mar","key":"10.1016\/j.jcv.2019.09.008_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1055-9965.EPI-09-0838","article-title":"Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study","volume":"19","author":"Constandinou-Williams","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"May (15)","key":"10.1016\/j.jcv.2019.09.008_bib0035","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/infdis\/jir049","article-title":"Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study","volume":"203","author":"Xi","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"April (15)","key":"10.1016\/j.jcv.2019.09.008_bib0040","first-page":"1747","article-title":"Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18","volume":"140","author":"Fu","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"September (14)","key":"10.1016\/j.jcv.2019.09.008_bib0045","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1111\/j.1582-4934.2012.01631.x","article-title":"Changes in type-specific human papillomavirus load predict progression to cervical cancer","volume":"16","author":"Depuydt","year":"2012","journal-title":"J. Cell. Mol. Med."},{"issue":"Suppl 1","key":"10.1016\/j.jcv.2019.09.008_bib0050","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcv.2015.09.014","article-title":"VALGENT: a protocol for clinical validation of human papillomavirus assays","volume":"76","author":"Arbyn","year":"2016","journal-title":"J. Clin. Virol."},{"issue":"April (30)","key":"10.1016\/j.jcv.2019.09.008_bib0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2019.09.008_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination","volume":"1","author":"von Karsa","year":"2015","journal-title":"Papillomavirus Res."},{"key":"10.1016\/j.jcv.2019.09.008_bib0065","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1515\/cclm.2011.835","article-title":"High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR","volume":"50","author":"Micalessi","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jcv.2019.09.008_bib0070","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2019.09.008_bib0075","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/JCM.01282-17","article-title":"Evaluation of the clinical performance of the HPV-Risk assay using the VALGENT-3 panel","volume":"55","author":"Polman","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.09.008_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcv.2017.12.001","article-title":"Assessment of the Roche linear Array HPV genotyping test within the VALGENT framework","volume":"98","author":"Xu","year":"2018","journal-title":"J. Clin. Virol."},{"issue":"September (11)","key":"10.1016\/j.jcv.2019.09.008_bib0085","article-title":"Clinical evaluation of INNO-LiPA HPV genotyping EXTRA II assay using the VALGENT framework","volume":"19","author":"Xu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"September (10)","key":"10.1016\/j.jcv.2019.09.008_bib0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcv.2018.09.005","article-title":"Validation of EUROArray HPV test using the VALGENT framework","volume":"108","author":"Viti","year":"2018","journal-title":"J. Clin. Virol."},{"issue":"September (12)","key":"10.1016\/j.jcv.2019.09.008_bib0095","first-page":"e01176","article-title":"Clinical and analytical evaluation of the Anyplex II HPV HR Detection assay within the VALGENT-3 framework","volume":"56","author":"Ostrbenk","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.09.008_bib0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2303.2007.00464.x","article-title":"European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology","volume":"18","author":"Arbyn","year":"2007","journal-title":"Cytopathology"},{"key":"10.1016\/j.jcv.2019.09.008_bib0105","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"issue":"50","key":"10.1016\/j.jcv.2019.09.008_bib0110","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1128\/JCM.01231-12","article-title":"Clinical validation of a type-specific real time quantitative human papillomavirus PCR to the performance of Hybrid Capture 2 for the purpose of cervical cancer screening","volume":"10","author":"Depuydt","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.09.008_bib0115","unstructured":"M.Ursic Vrscaj (Ed.). Society for gynecological oncology,colposcopy and cervical pathology,Slovenian guidelines for management of pathological cercical smears. http:, zora.onko-i.si\/fileadmin\/user upload\/dokumenti\/strokovna priporocila\/2011 Smernice web.pdf, editors. 2011."},{"issue":"May","key":"10.1016\/j.jcv.2019.09.008_bib0120","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/JCM.00012-11","article-title":"Comparison of clinical and analytical performance of the abbott realtime high risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening","volume":"49","author":"Poljak","year":"2011","journal-title":"J. Clin. Microbiol."},{"issue":"Apr (30)","key":"10.1016\/j.jcv.2019.09.008_bib0125","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/sim.1213","article-title":"On tests of equivalence via non-unity relative risk for matched-pair design","volume":"22","author":"Tang","year":"2003","journal-title":"Stat. Med."},{"issue":"February (1)","key":"10.1016\/j.jcv.2019.09.008_bib0130","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2019.09.008_bib0135","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3332\/ecancer.2015.526","article-title":"Role of human papillomaviruses in carcinogenesis","volume":"9","author":"Ghittoni","year":"2015","journal-title":"Ecancermedicalscience"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219302136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219302136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:11:54Z","timestamp":1761361914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653219302136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":27,"alternative-id":["S1386653219302136"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2019.09.008","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2019.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}